(Q37353135)

English

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

human subject research project

0 references

metabolic syndrome

1 reference

based on heuristic

inferred from title

author name string

John S Millar

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Danielle Duffy

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ramprasad Gadi

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

LeAnne T Bloedon

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Richard L Dunbar

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Megan L Wolfe

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Rajesh Movva

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ashish Shah

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ilia V Fuki

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Mary McCoy

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Cynthia J Harris

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ming-Dauh Wang

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Daniel C Howey

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Daniel J Rader

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

6 November 2008

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Arteriosclerosis, Thrombosis, and Vascular Biology

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

29

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

140-146

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Mechanism of action of gemfibrozil on lipoprotein metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

6 September 2017

Apolipoprotein A-II is inversely associated with risk of future coronary artery disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

14 September 2017

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

28 September 2017

Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

26 June 2018

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in seru

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distri

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746746

2 September 2018

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of LCAT in HDL remodeling: investigation of LCAT deficiency states

1 reference

https://pubmed.ncbi.nlm.nih.gov/18988892

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1161/ATVBAHA.108.171223

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37353135&oldid=1702040095"